HOME >> BIOLOGY >> NEWS
Millennium and Bayer industrializing drug discovery process through ongoing successful research alliance

o years has been extraordinary, particularly given the usual three-year timeframe for the processing of targets, chemistry and pharmacology necessary to yield a developmental drug candidate, said Professor Wolfgang Hartwig, executive vice president of pharmaceuticals research at Bayer. As we celebrate our second anniversary with Millennium, we anticipate that in addition to our screening pipeline of more than 70 targets, we will have several preclinical compounds and potentially one chemical compound nearing IND status by year-end.

In May 2000, Millennium and Bayer expanded the initial objectives of the alliance, based on the success of their efforts. The two companies collectively accelerated their second year goal of identifying new validated drug targets from 50 to 100 by the end of 2000. To date, more than 70 validated drug targets have been identified since the alliance began in September 1998.
Bayer and Millennium have created the worlds leading platform for biologically annotating targets and moving them into drug discovery, said Mark Levin, chief executive officer of Millennium. Our joint efforts exemplify the power of Millennium's genomics-based approach to drug discovery and development, Bayers cutting-edge screening and chemistry capabilities and expertise, and the extraordinary success which can be created through over-the-top alliances.

Alliance Background The primary goal of the alliance is for Millennium to supply 225 important new drug targets identified as relevant for cardiovascular disease, cancer, pain, hematology and viral infections. From those identified by the alliance, Bayer will select drug targets for its exclusive use and the remainder will be available to Millennium to use in its proprietary drug development efforts.

In return for a total investment of up to $465 million, including an equity investment in Millennium over a five-year period, Bayer receives access to key technologies in modern genome
'"/>

Contact: Maureen Suda, Millennium Pharmaceuticals Inc.
617-551-2959
Porter Novelli
23-Oct-2000


Page: 1 2 3

Related biology news :

1. Millenniums LDP(PS)-341 inhibits growth and induces death of cancer cells, appears to overcome chemotherapy resistance
2. Science and Technology at the Millennium: Retrospect or Prospect Focus of AAAS Science and Technology Colloquium, April 11-13 in Washington, DC
3. Millennium and Wyeth-Ayerst announce the discovery of key potassium ion channel modulating proteins
4. Millennium and the Whitehead Institute identify novel protein important in fat absorption
5. Millennium Clones Diet-Induced Obesity Gene
6. Protemix corporation announces discovery of way to repair hearts damaged by diabetes
7. New OHSU lab will speed drug discovery process
8. New discovery may help transplants survive
9. Genetic discovery could dramatically reduce need for liver transplants in children
10. Plant gene discovery could enhance plant growth, reduce fertilizer needs and phosphate pollution
11. Major scientific discovery in cancer research to be honored

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/6/2017)... -- Forecasts by Product Type (EAC), Biometrics, ... (Transportation & Logistics, Government & Public Sector, Utilities / ... Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality ... looking for a definitive report on the $27.9bn Access ... ...
(Date:4/4/2017)...   EyeLock LLC , a leader of iris-based ... Patent and Trademark Office (USPTO) has issued U.S. Patent ... an iris image with a face image acquired in ... 45 th issued patent. "The ... the multi-modal biometric capabilities that have recently come to ...
(Date:3/30/2017)... , March 30, 2017 Trends, opportunities ... (physiological and behavioral), by technology (fingerprint, AFIS, iris recognition, ... recognition, and others), by end use industry (government and ... immigration, financial and banking, and others), and by region ... , Asia Pacific , and ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... October 11, 2017 , ... ComplianceOnline’s Medical Device Summit is back for ... June 2018 in San Francisco, CA. The Summit brings together current and former FDA ... board directors and government officials from around the world to address key issues in ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... implantation and pregnancy rates in frozen and fresh in vitro fertilization (IVF) ... and maternal age to IVF success. , After comparing the results from the ...
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder and CEO of ... Rotary Club. The event entitled “Stem Cells and Their Regenerative Powers,” ... Dr. Harman, DVM, MPVM was joined by two human doctors: Peter B. Hanson, ...
(Date:10/9/2017)... SAN DIEGO , Oct. 9, 2017 /PRNewswire/ ... a biological mechanism by which its ProCell stem ... of critical limb ischemia.  The Company, demonstrated that ... the amount of limbs saved as compared to ... of the molecule HGF resulted in reduction of ...
Breaking Biology Technology:
Cached News: